Tag Archives: Zealand Pharma

Novo Triple Agonist T2DM Data; BI 2026 Annual Press Conference; Pfizer Doses First Patient in VESPER-5; Merck Acquires Terns; Fractyl Q4 ’25 Earnings; Biomea FY 2025 Updates; BrightGene Ph1 Dual Agonist Data

A series of cardiometabolic-related news items has been observed by Novo Nordisk, Boehringer Ingelheim, Pfizer, Merck, Fractyl Health, Biomea Fusion, and BrightGene Bio-Medical Technology. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Zealand Establishes Boston Research Hub; Aardvark Pipeline on Hold; Rezolute Shares CHI Program Updates; Rivus New MASH Trial

A series of cardiometabolic-related news items has been observed by Zealand Pharma, Aardvark Therapeutics, Rezolute, and Rivus Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Topline Petrelintide Ph2 Results; Potential Brand Name for Orforglipron?; New Novo Ph1 Obesity Asset; Altimmune and Lexicon Q4 ’25 Earnings; Lilly Launches New DTE Platform; Tandem Mobi Now Available on Android

A series of cardiometabolic-related news items has been observed from Zealand/Roche, Lilly, Novo Nordisk, Altimmune, Lexicon, and Tandem Diabetes Care. Below, FENIX provides highlights and insights on the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Obesity Power Rankings: Who Will Challenge Lilly and Novo?

Earlier this week on FiercePharma, an abbreviated version of FENIX’s Obesity Power Rankings was published (view article). Below is the complete version.

This content is for Read Less members only.
Register

Already a member? Log in here

Zealand and Madrigal Q4 ’25 Earnings; Novo Initiates Ph2 T2DM Study of Internal Triple-Agonist; Goodpath Expands Wegovy Access

A series of cardiometabolic-related news items has been observed from Zealand Pharma, Novo Nordisk, Madrigal Pharmaceuticals, and Goodpath. Below, FENIX provides highlights and insights on the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Beta Bionics and Insulet Q4 ’25 Earnings; Lilly Taltz+Zepbound PsO Combination Data; Zealand Ph1a Kv1.3 Inhibitor Topline Results

A series of cardiometabolic-related news items has been observed from Beta Bionics, Insulet, Lilly, and Zealand Pharma. Below, FENIX provides highlights and insights on the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

JPM 2026 Day 3: ZLDPF, ABBV, SANA, PODD; Jazz to Sell PRV; Novo Initiates Amycretin Ph3 Program; Madrigal Initiates New Ph2 Resmetirom MASH Study; Sandoz Confirms EC Approval of Ondibta

On the third day of JPM 2026, FENIX has provided coverage of presentations by major CVRM companies, including Zealand, AbbVie, Sana Biotechnology, and Insulet. Separately, a series of CVRM-related news items has been observed. Below, FENIX provides highlights and insights for the respective news items, including speculation into who purchased Jazz’s PRV.

This content is for Read Less members only.
Register

Already a member? Log in here

Madrigal Licenses MASH Assets from Pfizer; Wegovy Pill Available on Amazon; New BI MASH Asset; Alveus Launches as Clinical-Stage Biotech; Zealand Partners for AI Drug Discovery; Lilly Expands TuneLab

A series of cardiometabolic-related news items has been observed from Madrigal/Pfizer, Novo Nordisk, Boehringer Ingelheim, Alveus Therapeutics, Zealand Pharma, and Lilly. Below, FENIX provides highlights and insights into the respective news items, including speculation into BI’s new MASH asset MOA.

This content is for Read Less members only.
Register

Already a member? Log in here

Zealand 2025 CMD and Partnership for Obesity Drug Discovery; Lilly Shares Topline Retatrutide Results; Corbus Topline CB1 Data; Dexcom Launches G7 15 Day CGM; Prolynx Series A Funding and Names CEO

A series of cardiometabolic-related news items has been observed from Zealand Pharma, Lilly, Corbus Pharmaceuticals, Dexcom, and Prolynx. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register

Already a member? Log in here

Zealand to Receive PRV?; Zealand Q3 ’25 Earnings; Pfizer Completes Metsera Acquisition; WeightWatchers to Offer Oral Wegovy; Ascletis Preclinical Combination Data; MangoRx Partners with NovoCare and LillyDirect?

A series of cardiometabolic-related news items has been observed from Pfizer/Metsera, Zealand Pharma, WeightWatchers, Ascletis Pharma, and Lilly/Mangoceuticals (MangoRx). Below, FENIX provides highlights and insights for the respective news items, including how Zealand can use a PRV to decrease the review time of petrelintide.

This content is for Read Less members only.
Register

Already a member? Log in here